论文部分内容阅读
目的 分析单药紫杉醇治疗晚期乳腺癌剂量强度与疗效和毒性的关系。方法 71例晚期乳腺癌患者 ,接受不同剂量强度的单药紫杉醇治疗。根据国际推荐方案 (每 3周 175mg/m2 ) ,标准剂量强度定义为每周 5 8.3mg/m2 。本组患者给药剂量范围每周 33.3～ 70 .3mg/m2 ,中位剂量强度为每周 5 8.8mg/m2 。评估紫杉醇剂量强度与疗效及毒性的关系。结果 全组患者的总有效率为4 0 .8% ,其中肺、软组织、骨及肝脏转移者 ,有效率分别为 5 2 .0 %、38.0 %、12 .5 %和 7.7%。相对剂量强度 >1.0、0 .9～ 1.0和 <0 .9时 ,全组患者的有效率分别为 4 4 .2 %、4 7.6 %和 0 ;相对剂量强度 0 .9～1.0和 <0 .9比较 ,差异有统计学意义 (P <0 .0 5 )。患者对毒副作用耐受良好 ,随着相对剂量强度降低 ,疗效降低 ,但毒性不减低。结论 单药紫杉醇治疗晚期乳腺癌患者时 ,按标准剂量强度应用是安全有效的。
Objective To analyze the relationship between the dose intensity of single-agent paclitaxel in the treatment of advanced breast cancer and its efficacy and toxicity. Methods 71 cases of advanced breast cancer patients received different doses of single-agent paclitaxel treatment. According to the International Recommendations (175mg / m2 every 3 weeks), the standard dose intensity is defined as 8.33mg / m2 weekly. This group of patients administered dose range 33.3 ~ 70.3mg / m2 per week, the median dose intensity of 5 8.8mg / m2 per week. Evaluate the relationship between paclitaxel dose intensity and efficacy and toxicity. Results The total effective rate of all patients was 40.8%. The effective rates of lung, soft tissue, bone and liver metastasis were 52.0%, 38.0%, 12.5% and 7.7% respectively. When the relative dose intensity was> 1.0,0. 9-1.0 and <0.9, the effective rates of the whole group of patients were 44.2%, 37.6% and 0 respectively; the relative dose intensity was 0.9-1.0 and <0. 9, the difference was statistically significant (P <0.05). Toxicity and side effects in patients with good tolerance, with the relative dose intensity decreased, curative effect decreased, but the toxicity is not reduced. Conclusions Single-agent paclitaxel is safe and effective for patients with advanced breast cancer at standard dose strengths.